실적분석 2026년 8월 26일

Veeva Systems ($VEEV) FY2027 Q2 Earnings Analysis — Revenue and Adjusted EPS Beat, Full-Year Outlook Raised

Earnings Scorecard

Revenue: $928M (+18% YoY, vs. $905M estimate) ✅ Beat

EPS (Earnings Per Share): Adjusted diluted $2.35 (vs. $2.22 estimate) ✅ Beat

Guidance: Raised — FY2027 revenue $3.682–3.687B, adjusted diluted EPS ~$9.21

Stock Reaction: +9.02% after-hours ($267) — as of 08-27 06:04 KST

Positives

Revenue and EPS Beat: Revenue $928M (+18%), adjusted EPS $2.35 topped the $2.22 estimate

Vault CRM Expansion: Live customers surpassed 180, expanded to 12 of the global top 20 pharma accounts

Full-Year Outlook Raised: CFO noted full-year visibility improved across the board, updating revenue and adjusted EPS

This was a quarter in which life sciences-specific cloud demand spread evenly across commercial and R&D. With AI agents and large pharma order wins moving at once, the growth story carried through to results.

Negatives

Subscription Growth Relatively Soft: Subscription revenue grew +16%, below total revenue (+18%), as professional services revenue (+24%) took a larger share

Flat EPS Guidance Next Quarter: Q3 adjusted diluted EPS guide of $2.33–$2.34 is roughly in line with the current quarter

Litigation Settlement Cost: G&A includes ~$30.63M in litigation settlement-related expenses

If professional services grow faster than subscriptions, the margin mix can deteriorate. Because next quarter's EPS guide is roughly in line with this quarter, it remains to be seen whether growth translates directly to earnings.

What Management Said

The CEO emphasized that AI is opening the next chapter for the company and the life sciences industry, highlighting the acceleration of Vault CRM and Vault Training. The CFO explained that every metric exceeded guidance and that full-year visibility is better across the board, which the market appears to have taken as a signal that results and outlook are improving together.

Market Reaction and What to Watch

The combination of revenue and adjusted earnings beats with an improved full-year view tilted the tape toward buyers.

Whether Vault CRM continues adding top pharma accounts and go-lives

Whether AI products such as Vault Training achieve their first go-lives this year on schedule

Whether subscription revenue growth re-converges with overall growth